Skip to main content Skip to section navigation Skip to footer
ProMIS Neurosciences, Inc.
  • Home
  • About Us
    • Overview
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
    • Business Advisory Board
  • Our Science
  • Product Pipeline
    • Overview
    • Alzheimer’s Disease
    • ALS
    • Parkinson’s Disease
    • Posters & Publications
  • News & Media
    • Press Releases
    • Corporate Presentations
    • Events
    • In The News
    • Videos
    • Commentary
    • Podcasts
  • Investors
    • Overview
    • News & Events
    • Company Info
    • Financial Results
    • Stock Data
    • SEDAR
    • SEC Filings
    • Governance
  • Careers
  • Contact

In The News

News & Media

News & Media

  • Press Releases
  • Corporate Presentations
  • Events
  • In The News
  • Videos
  • Commentary
  • Podcasts
Sep 19, 2017

ProMIS Neurosciences could have a groundbreaking Alzheimer’s treatment, Mackie Research says

Sep 13, 2017

Reuters: BRIEF-ProMIS Neurosciences designates PMN330 as 3rd, validated lead product for development in alzheimer’s disease

Aug 9, 2017

Life Science Leader: Company to Watch: ProMIS Neurosciences

Aug 2, 2017

BRIEF-Promis Neurosciences increases size of private placement to $6 mln

Jul 31, 2017

‘Ninja drug’ prevents Alzheimer’s by destroying harmful cells in the brain

Jul 18, 2017

Biotech with Alzheimer's Focus Makes Progress on Several Fronts

Jul 17, 2017

Alzheimer's drug developers still hoping for a homer

May 9, 2017

BRIEF-Promis Neurosciences reports q1 2017 annual results

May 3, 2017

The ProMIS of an Alzheimer's Cure

rss_feed RSS
  • arrow_back
  • 1
  • 2
  • 3
  • 4
  • 5
Facebook Linkedin Spotify Twitter
©2022 ProMIS Neurosciences, Inc. All Rights Reserved.
Disclaimer Sitemap Cookie Policy Privacy Policy